REGN17092
/ Regeneron
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
September 03, 2025
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN17092, an YTE modified Anti-SARS-COV-2 (COVID-19) Monoclonal Antibody in Adult Healthy Volunteers
(IDWeek 2025)
- No abstract available
Clinical • P1 data • PK/PD data • Infectious Disease • Novel Coronavirus Disease
March 27, 2025
A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: Regeneron Pharmaceuticals | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
April 26, 2024
An update on the anti-Spike monoclonal antibody pipeline for SARS-CoV-2.
(PubMed, Clin Microbiol Infect)
- "The anti-Spike monoclonal antibody clinical pipeline is currently limited to few agents (most being single antibodies) with unknown efficacy against the dominant JN.1 sublineage. The field of antibody-based therapies requires boosting by both manufacturers and institutions."
Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
March 12, 2024
A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
(clinicaltrials.gov)
- P1 | N=40 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=128 ➔ 40
Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
December 13, 2023
A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
(clinicaltrials.gov)
- P1 | N=128 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2024 ➔ Apr 2025 | Trial primary completion date: Nov 2024 ➔ Apr 2025
Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
June 28, 2023
A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
(clinicaltrials.gov)
- P1 | N=128 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 6
Of
6
Go to page
1